Everolimus in Pancreatic Neuroendocrine Tumors OncLive In May 2011, the FDA approved everolimus as a treatment for patients with advanced progressive pancreatic neuroendocrine tumors (pNET) based on findings from the phase III RADIANT-3 trial. In the pivotal trial, progression-free survival was 11.0 months ... |
